Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 9.80% is 54% below its 2-year average of 21.16%, near the low end of its 2-year range (9.80%–25.22%).
As of the fiscal period ended Tuesday, March 31, 2026. 49.86% below its 12-month average of 19.53%.
Reported quarterly debt to assets ratio; no daily interpolation. Q4 FY2026 (2026-03-31): 9.80%.
DEBT TO ASSETS RATIO
9.80%
DEBT TO ASSETS RATIO AVG TTM
19.53%
DEBT TO ASSETS RATIO AVG 3Y
N/A
DEBT TO ASSETS RATIO AVG 5Y
N/A
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-49.86%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+10783.94%
vs the sector median at left
Cellyan Biotechnology Co., Ltd
Market Cap
$1.11M
Debt to Assets Ratio
9.80%
TTM Avg
19.53%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.12M
Debt to Assets Ratio
0.04%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.08M
Debt to Assets Ratio
0.11%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.01M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$946332.00
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$901902.00
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.34M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cellyan Biotechnology Co., Ltd (HKPD) | $1.11M | 9.80% | 19.53% | N/A | N/A |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.12M | 0.04% | N/A | N/A | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.08M | 0.11% | N/A | N/A | N/A |
| IM Cannabis Corp. (IMCC)vs › | $1.17M | 0.56% | N/A | N/A | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.01M | 0.00% | N/A | N/A | N/A |
| Sunshine Biopharma, Inc. (SBFM)vs › | $946332.00 | 0.02% | N/A | N/A | N/A |
| Genprex, Inc. (GNPX)vs › | $1.32M | 0.00% | N/A | N/A | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $901902.00 | 0.01% | N/A | N/A | N/A |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.34M | 0.01% | N/A | N/A | N/A |
| Bone Biologics Corporation (BBLG)vs › | $868077.00 | 0.00% | N/A | N/A | N/A |
Debt/Assets
9.8%
Debt/Equity
0.13
Current Ratio
3.86
Interest Coverage
-7.5x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-03-31 | 9.80% |
| 2025-09-30 | 23.59% |
| 2025-03-31 | 25.22% |
| 2024-09-30 | 23.11% |
| 2024-03-31 | 24.08% |
